MedTrace Logo

Dasotraline Binge Eating Disorder Extension Study

NCT02684279 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 533

Last updated 2020-08-12

Study results available
· View outcomes & findings →

Summary

Binge Eating Disorder Extension Study.

Conditions

  • Binge Eating Disorder

Interventions

DRUG

Dasotraline

Dasotraline 4, 6, 8 mg flexibly dosed once daily

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Dasotraline Medical Director · Sumitomo Pharma America, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
56 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-06-24
Completion
2019-06-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02684279 on ClinicalTrials.gov